Split Autoimmune Readouts Reframe the argenx Expansion Thesis
argenx disclosed two clinically material but directionally opposed signals on October 8. An independent data monitoring committee concluded that the Phase 3 UNITY study of subcutaneous efgartigimod in moderate-to-severe Sjogren disease could not meet…
